Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 29;12(7):e062126.
doi: 10.1136/bmjopen-2022-062126.

Criteria to define rare diseases and orphan drugs: a systematic review protocol

Ghada Mohammed Abozaid  1   2 , Katie Kerr  2 , Amy McKnight  2 , Hussain A Al-Omar  3   4   5
Affiliations

Criteria to define rare diseases and orphan drugs: a systematic review protocol

Ghada Mohammed Abozaid et al. BMJ Open. .

Abstract

Introduction: Rare diseases (RDs) are often chronic and progressive life-threatening medical conditions that affect a low percentage of the population compared with other diseases. These conditions can be treated with medications known as orphan drugs (ODs). Unfortunately, there is no universal definition of RDs or ODs. This systematic review (SR) will identify the quantitative and qualitative criteria and the underlying rationale used internationally to define RDs and ODs.

Methods and analysis: This protocol follows the conventions for the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (2015 guidelines). A SR will be conducted, including a search of the following databases: PubMed, MEDLINE, EMBASE, Scopus, Web of Science, GreyLit and OpenGrey. Eligible publications will be selected based on predetermined inclusion criteria. Extracted data will be analysed using thematic and content analyses of qualitative descriptors, whereas quantitative data will be analysed descriptively and reported in the form of frequencies and percentages.

Ethics and dissemination: No ethical approval is required since this SR focuses on the secondary analysis of data retrieved from the scientific literature. The outcomes of this SR will be published as part of a PhD thesis, presented at conferences, and published in peer-reviewed journals.

Prospero registration number: CRD42021252701.

Keywords: epidemiology; health economics; health policy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Gorini F, Coi A, Mezzasalma L, et al. Survival of patients with rare diseases: a population-based study in Tuscany (Italy). Orphanet J Rare Dis 2021;16:275. 10.1186/s13023-021-01907-0 - DOI - PMC - PubMed
    1. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 2020;28:165–73. 10.1038/s41431-019-0508-0 - DOI - PMC - PubMed
    1. Population matters . Current world population, 2022. Available: https://populationmatters.org/population-numbers?gclid=EAIaIQobChMIjcjIl...
    1. Chan AYL, Chan VKY, Olsson S, et al. Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis. Value Health 2020;23:1580–91. 10.1016/j.jval.2020.06.020 - DOI - PubMed
    1. Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-A systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015;18:906–14. 10.1016/j.jval.2015.05.008 - DOI - PubMed

Publication types